Table 1 Descriptive statistics of 44 included studies.
Characteristics | Studies with characteristics, No. (%) |
---|---|
Country | |
North America | 12 (27.27) |
Europe | 20 (45.45) |
Australia | 10 (22.73) |
Asia | 2 (4.55) |
Sample size, mean (SD) [range] | |
Total | 115.39 (122.48) [15–562] |
Intervention group | 59.30 (63.07) [7–280] |
Control group | 51.07 (54.26) [8–282] |
Risk of bias | |
High risk | 17 (38.64) |
Some concerns | 24 (54.55) |
Low risk | 3 (6.82) |
Attrition rate at post-intervention | |
High (>20%) | 7 (15.91) |
Moderate (5–20%) | 32 (72.73) |
Low (<5%) | 5 (11.36) |
Control group type | |
Active control | 21 (47.73) |
Non-active control | 24 (54.55) |
Inclusion of follow-up data | |
First follow-up data reported | 19 (43.18) |
Last follow-up data reported | 6 (13.64) |
Follow-up duration after intervention (weeks) | |
First follow-up, mean (SD) [range] | 15.78 (7.31) [8–36] |
Last follow-up, mean (SD) [range] | 26 (12.81) [12–48] |
Psychiatric symptoms | |
Depressive symptoms | 39 (88.64) |
Anxiety symptoms | 30 (68.18) |
Depressive and anxiety symptoms | 6 (13.64) |
Post-traumatic stress disorder (PTSD) symptoms | 3 (6.82) |
General psychological distress | 10 (22.73) |
Physical distress | |
Physical symptoms | 27 (61.36) |
Functional impairment | 19 (43.18) |
Self-rated ill health | 4 (9.09) |
Objective physiological dysfunction | 2 (4.55) |
Proportion of female, mean (SD) [range] | 71.11% (18.97%) [28.81%–100.00%] |
Age of all included patients, mean (SD) [range] | 47.61 (13.27) [11–91] |
Chronic diseases | |
Chronic pain | 19 (43.18) |
Cancer | 7 (15.91) |
Arthritis | 6 (13.64) |
Cardiovascular disease | 4 (9.09) |
Diabetes | 2 (4.55) |
HIV | 1 (2.27) |
Multiple sclerosis | 1 (2.27) |
Different chronic diseases | 4 (9.09) |
Physical or psychiatric comorbidity | |
Yes | 23 (52.27) |
No | 21 (47.73) |
Medication received for physical condition(s) | |
Yes | 22 (50.00) |
No | 22 (50.00) |
Surgery received for physical condition(s) | |
Yes | 6 (13.64) |
No | 38 (86.36) |
Supplement and/or other received for physical condition(s) | |
Yes | 5 (11.36) |
No | 39 (88.64) |
Medication received for psychiatric condition(s) | |
Yes | 12 (27.27) |
No | 32 (72.73) |
Psychotherapy received for psychiatric condition(s) | |
Yes | 3 (6.82) |
No | 41 (93.18) |
Intervention delivery platform | |
Videoconference | 3 (6.82) |
Web-based | 39 (88.64) |
Mobile app | 3 (6.82) |
Guidance | |
Guided | 32 (72.73) |
Unguided | 14 (31.82) |
Intervention duration (no. of sessions) | |
Short (<12 sessions) n (%) [range] | 35 (79.55) [4–10] |
Medium/long (≥12 sessions) n (%) [range] | 9 (20.45) [12–48] |
Therapeutic elements | |
Behavioral modification | 43 (97.73) |
Cognitive restructuring | 30 (68.18) |
Problem-solving | 43 (97.73) |
Psychoeducation | 37 (84.09) |
Mindfulness | 28 (63.64) |
Intention-to-treat analysis | |
Yes | 33 (75.00) |
No | 11 (25.00) |